logo

For the Inventor, By the Inventor

Rehovot, Israel

Michal Eisenbach-Schwartz

USPTO Granted Patents = 42 

 

 

Average Co-Inventor Count = 3.2

ph-index = 12

Forward Citations = 455(Granted Patents)


Company Filing History:

goldMedal42 out of 1,168 
 
Yeda Research and Develpment & Co. Ltd
 patents
silverMedal2 out of 2 
 
Immunobrain Checkpoint, Inc.
 patents
where one patent can have more than one assignee

Years Active: 1998-2024

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Regulatory T Cells
Neurodegenerative Diseases
Amyotrophic Lateral Sclerosis
Alzheimer's Disease
Retinal Degeneration
Mononuclear Phagocytes
Neuronal Protection
Vaccine Development
Eye Diseases
Central Nervous System Injury
Kisspeptin Peptides
Neuroprotective Therapy
42 patents (USPTO):Explore Patents
1. 11884728 - Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis (2024-01-30),
2. 11884727 - Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis (2024-01-30),
3. 11732046 - Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease (2023-08-22),
4. 11643464 - Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder (2023-05-09),
5. 11492405 - Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS (2022-11-08),
6. 10995141 - Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease (2021-05-04),
7. 10981989 - Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS (2021-04-20),
8. 10961309 - Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS (2021-03-30),
9. 10618963 - Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS (2020-04-14),
10. 10519237 - Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS (2019-12-31),
11. 10214585 - Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS (2019-02-26),
12. 10188679 - Human monocyte sub-population for treatment of eye diseases and disorders (2019-01-29),
13. 10144778 - Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS (2018-12-04),
14. 9982051 - Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS (2018-05-29),
15. 9982050 - Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease (2018-05-29),

Title: The Innovative Mind of Michal Eisenbach-Schwartz

Introduction: Michal Eisenbach-Schwartz is a visionary inventor hailing from Rehovot, Israel, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Michal Eisenbach-Schwartz holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and forward-thinking approach to problem-solving.

Career Highlights: With a career spanning over two decades, Michal Eisenbach-Schwartz has worked with leading research institutions and tech companies, spearheading projects that have revolutionized industries and improved the lives of many.

Collaborations: Throughout his career, Michal Eisenbach-Schwartz has collaborated with top scientists, engineers, and entrepreneurs, fostering a culture of innovation and creativity that has led to numerous successful projects and inventions.

Conclusion: Michal Eisenbach-Schwartz continues to push the boundaries of what is possible, inspiring the next generation of inventors and leaving a lasting impact on the world of technology and innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…